Details for New Drug Application (NDA): 202278
✉ Email this page to a colleague
The generic ingredient in ZECUITY is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
Summary for 202278
Tradename: | ZECUITY |
Applicant: | Teva Branded Pharm |
Ingredient: | sumatriptan succinate |
Patents: | 9 |
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | SYSTEM;IONTOPHORESIS | Strength | EQ 6.5MG BASE/4HR | ||||
Approval Date: | Jan 17, 2013 | TE: | RLD: | Yes | |||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 12, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 12, 2027 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA,COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF | ||||||||
Patent: | ⤷ Sign Up | Patent Expiration: | Apr 21, 2029 | Product Flag? | Substance Flag? | Delist Request? | |||
Patented Use: | METHOD FOR TREATING ACUTE MIGRAINE IN ADULTS, WITH OR WITHOUT AURA, COMPRISING IONTOPHORETIC TRANSDERMAL DELIVERY OF SUMATRIPTAN OR A SALT THEREOF, USING A FLOWABLE HYDROGEL FORMULATION |
Expired US Patents for NDA 202278
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Teva Branded Pharm | ZECUITY | sumatriptan succinate | SYSTEM;IONTOPHORESIS | 202278-001 | Jan 17, 2013 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription